|
A multicentre, phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the oesophagogastric junction and stomach (CABAGAST). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Merck; MSD; Novartis; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Boehringer Ingelheim; Sanofi; Teva |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Astellas Oncology; Ipsen |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bayer; GlaxoSmithKline; Lilly; Novartis; Pfizer; PharmaMar |
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Clinigen Group; GlaxoSmithKline; Lilly; Novartis; Pfizer; PharmaMar |
Research Funding - Novartis (Inst) |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Janssen-Cilag; Lilly; Ribosepharm |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Lilly; Merck; Roche; SERVIER |
Speakers' Bureau - Celgene; Lilly; Nordic Bioscience; Roche |
Research Funding - Celgene; Hospira; Lilly; Medac; Novartis; Roche Pharma AG; Vifor Pharma |
|
|
|
Consulting or Advisory Role - Baxalta; Bristol-Myers Squibb |